September 2019—Randox launched at the AACC annual meeting the Randox Stroke Biochip, a highly sensitive blood test that complements CT scanning technology to facilitate accurate classification of stroke patients. The test differentiates between ischemic and hemorrhagic stroke, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy. The Randox Biochip runs on the company’s Evidence MultiStat and takes less than 30 minutes to complete.
The company also introduced at AACC its Acusera Infectious Disease (Serology) Controls. The microanalyte controls include quality control material for Lyme disease, ToRCH, Epstein-Barr virus, HIV, hepatitis A virus, human T-lymphotropic virus, cytomegalovirus, and varicella-zoster virus. The ready-to-use controls can be used with any immunoassay instrument, are manufactured from human plasma, and have a working stability of 60 days at 2°–8°C.
Randox’s Qnostics whole pathogen Blood Borne Virus controls were also unveiled at AACC. The molecular controls monitor the presence of BBVs, including HIV, hepatitis B, and hepatitis C. They are liquid frozen, are designed to be medium positive, and are suitable for use with a variety of molecular workflows.
Randox, 866-472-6369